Cellular Biomedicine Moves to NASDAQ Capital Market

Cellular Biomedicine began trading on the NASDAQ Capital Market today. The company is headquartered in Palo Alto, California, and it has two GMP facilities in China: one in Shanghai and the other in WuXi. Cellular Biomedicine develops cell therapy treatments for degenerative diseases and cancer, which it plans to market in China. Previously, Cellular Biomedicine was listed on the OTCQB exchange. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //